Study title: Schellong-G, Poetter-R, Braemswig-J, Wagner-W, Prott-F-J, Doerffel-W, Koerholz-D, Mann-G, Rath-B, Reiter-A, Weissbach-G, Riepenhausen-M, Thiemann-M, Schwarze-E-W. Department of Pediatric Hematology and Oncology, University Children's Hospital, Germany. schellon@uni-muenster.de. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German- Austrian Pediatric Hodgkin's Disease Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, {J-Clin-Oncol}, Dec 1999, vol. 17, no. 12, p. 3736-44, ISSN: 0732-183X.Schellong-G, Poetter-R, Braemswig-J, Wagner-W, Prott-F-J, Doerffel-W, Koerholz-D, Mann-G, Rath-B, Reiter-A, Weissbach-G, Riepenhausen-M, Thi...
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms [C04] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: PROCARBAZINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |